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Caveolin-2isoneofthemajorproteincomponentsofcholesterol-andglycosphingolipid-richﬂask-shapedinvaginationsofplasma
membranecaveolae.Anewbody ofevidencesuggeststhatcaveolin-2playsanimportant,andoftenmoredirect,rolethancaveolin-
1 in regulating signaling and function in a cell- and tissue type-speciﬁc manner. The purpose of this paper is to primarily focus
on discussing how these recent discoveries may help better understand the speciﬁc contribution of caveolin-2 to lipid raft- and
caveolae-regulated cell/tissue-speciﬁc signaling and functions.
1.Introduction
Caveolinsarecriticalmembraneproteinsofcholesterollipid-
rich lipid rafts and caveolae. Three members are known
within the caveolin protein family: caveolin-1 (Cav-1), Cav-
2, and Cav-3 [1]. Cav-1 and -2 are ubiquitously coexpressed,
while Cav-3 is muscle-speciﬁc [1]. Cav-2 tightly interacts
with Cav-1 and forms hetero-oligomeric complexes within
caveolae [2, 3]. The interaction with Cav-1 is necessary
for transport of Cav-2 to the cell surface [4, 5]. In the
absence of Cav-1, Cav-2 is degraded, and its expression is
strikinglyreduced[6,7].Caveolinsplaynumerousimportant
functions. In addition to being key structural proteins that
organize caveolar structures, caveolin proteins are important
in regulating various aspects of cell signaling and func-
tion [1, 8–11]. Although relative to Cav-1, the functional
role of Cav-2 is poorly deﬁned, and recent studies have
started to reveal a growing body of evidence suggesting
tissue/cell-speciﬁc role for Cav-2. This paper discusses the
involvement of Cav-2 in signaling and function, with a
particular emphasis of how Cav-2 may contribute to tissue-
and cell-speciﬁc function of lipid raft and caveolar micro-
domains.
2.Cell Type-SpeciﬁcRoleforCav-2inCaveolae
FormationandTurnOver
Unlike the indispensable role for Cav-1 in caveolae assembly
in nonmuscle cells and the respective role of Cav-3 in muscle
cells, the role of Cav-2 is less clear. Caveolae have been iden-
tiﬁed in ultrathin sections from lung capillary endothelium
and in perigonadal adipose tissue of Cav-2 knockout (KO),
suggesting that Cav-2 is not necessary for caveolae forma-
tion, at least, in the aforementioned tissues [12]. However, a
more thorough examination of other organs and tissues may
be required to determine the overall distribution of caveolae
in Cav-2 KO mice. Most importantly, it remains to be estab-
lished if and how the function of Cav-2-devoidcaveolae may
be altered relative to WT. In contrast to the observations
made in Cav-2 KO mice, there are several studies indepen-
dently indicating supportive or essential role of Cav-2 in the
caveolae formation in various epithelial cell lines. For exam-
ple, Scheiﬀele et al., 1998 [13], who were using immunogold
labeling, followed by electron microscopy, noticed that in
the polarized epithelial cell line MDCK, Cav-1 and -2 are
found together on basolateral caveolae, whereas the apical
membrane, where only Cav-1 is present lacks caveolae. This2 Biochemistry Research International
observation suggests that Cav-1 and -2 heterooligomers, but
not Cav-1 homooligomers, are essential for caveolar bio-
genesis in MDCK cells. A follow-up study revealed that the
expression of Cav-1mutant, which prevented the formation
of the large Cav-1/-2 hetero-oligomeric complexes, led to
intracellular retention of Cav-2 and loss of caveolae, while
overexpression of wild-type (WT) Cav-2 increased number
of caveolae, thus supporting the role of Cav-2 in caveolar
biogenesis in MDCK cells [14]. Independently, using freeze-
fracture immunoelectron microscopy, Fujimoto and col-
leagues [15] have shown that coexpression of Cav-1 and
Cav-2resulted in a more eﬃcient formation of deepcaveolae
than Cav-1 alone in hepatocellular carcinoma cell line
(HepG2). Using electron microscopy, we have previously
shown that in addition to Cav-1, Cav-2 is also essential for
de novo assembly of caveolae in human prostate cancer cell
line LNCaP[3]. Furthermore, thestimulatory eﬀectofCav-2
on caveolae assembly in LNCaP cells depended on the con-
stitutive phosphorylation of Cav-2 at serine residues 23 and
36 by casein kinase 2 or a casein kinase 2-like kinase.
Mutationofserine residues 23 and 36 to alanine, reduced the
number of plasmalemma-attached caveolae and increased
the accumulation of noncoated vesicles but did not aﬀect
traﬃcking of Cav-2 to caveolae and interaction with
Cav-1 resulting in a formation of high molecular weight
heterooligomeric complexes [3]. Although serine 23 phos-
phorylation did not aﬀect caveolae assembly per se, it
cooperated with serine 36 during caveolae biogenesis.
Remarkably,S23A-Cav-2increased thenumberofnoncoated
vesicles in proximity to plasma membrane, suggesting that
serine 23 phosphorylation could be important for plasma
membrane caveolae turnover and traﬃcking.
3.Serine23 PhosphorylationasaSpeciﬁc
Markerof Cav-2Targetingto Plasma
Membrane CaveolaeandLipidRaftsin
Epithelialand EndothelialCells
Because in addition to plasma membrane caveolae and lipid
rafts, Cav-2canexistinothersubcellularcompartmentssuch
as ER, Golgi, cytosolic vesicles, lipid droplets, or nucleus, we
have decided to examine if serine phosphorylation of Cav-
2 depends on subcellular location. Using a combination of
reconstituted epithelial cell-based systems such as LNCaP
and FRT cells as well as endogenously expressing caveolins
primary human endothelial cells, we have examined if phos-
phorylation ofCav-2at serines 23and 36 can be regulated by
Cav-1 and subcellular targeting to noncaveolar intracellular
compartments versus plasma membrane lipid raft/caveolae
intheaforementionedepithelialandendothelialcells.Specif-
ically, detergent insolubility and sucrose ﬂotation gradients
experiments revealed that Cav-2 was phosphorylated at
serine 23 primarily in detergent resistant microdomains
(DRMs). In contrast, serine 36 phosphorylation occurred in
non-DRMs. Furthermore, immunoﬂuorescence microscopy
studies determined that in the presence of Cav-1 ser-
ine 23-phosphorylated Cav-2 localized mostly to plasma
membrane, while serine 36-phosphorylated Cav-2 primarily
resided in intracellular perinuclear regions. To directly ad-
dress the role of Cav-1 in regulating phosphorylation of
endogenous Cav-2, we have used siRNA approach. The
speciﬁc knockdown of Cav-1 in human endothelial cells de-
creased Cav-2 phosphorylation at serine 23 but not serine
36. Thus, upregulation of serine 23 phosphorylation of Cav-
2 depends on Cav-1-driven targeting to plasma membrane
lipid rafts and caveolae [16].
4.Tyrosine 19and 27 Phosphorylationof
Cav-2:RegulationandPotentialRolein
Cell Signaling andFunctioninor outof
LipidRafts/Caveolae?
Cav-2 has beenshown to undergoSrc-induced phosphoryla-
tion on tyrosine 19, using phosphotyrosine 19 (pY 19)-Cav-
2-speciﬁc antibody in NIH-3T3 cells stably overexpressing
c-Src. Stimulation of adipocytes with insulin resulted in
increase in pY 19-Cav-2. Unlike total Cav-2, pY 19-Cav-2
primarily localized near focal adhesion sites. Using Gst-fused
Cav-2, several Src homology 2 (SH2) domain containing
proteins were identiﬁed, such as c-Src, Nck, and Ras-GAP
to potentially interact with Cav-2 in a phosphorylation-
dependent manner. These data suggest that tyrosine 19-
phosphorylated Cav-2 could possibly be a docking site for
SH2 domain containing proteins [17]. Interestingly, pY 19-
Cav-2 remained associated with lipid rafts/caveolae, but
no longer formed high molecular mass hetero-oligomeric
complexeswith Cav-1.Therefore, theauthorsconcludedthat
phosphorylation of Cav-2 at tyrosine 19 may act as a signal
dissociating Cav-2 from Cav-1 oligomers [17]. However, be-
cause Cav-2 requires Cav-1 for caveolar association, it is
diﬃcult to reconcile this concurrent lipid raft/caveolar asso-
ciation of pY 19-Cav-2 with a loss of interaction with Cav-
1. Further studies may be required to thoroughly investigate
this intriguing regulation. For example, coimmunoprecipi-
tation experiments with Cav-1 and -2 antibodies could be
performed to test if pY 19-Cav-2/Cav-1 interaction is indeed
lost.
In addition to tyrosine 19, Cav-2 can also be phospho-
rylated at tyrosine 27. Remarkably, pY 27-Cav-2 appeared
to be more critical than pY 19-Cav-2 for binding c-Src,
Nck, and Ras-GAP. EGF stimulated Cav-2 phosphorylation
at both tyrosines 19 and 27 in A431 cells; however, the
temporal response to EGF was diﬀerent; that is, Cav-2 was
phosphorylated at tyrosine 19 in a rapid and transient fash-
ion, whereas phosphorylation at tyrosine 27 was sustained.
Interestingly, just as pY 19-, pY 27-Cav-2 also associated
with lipid rafts/caveolae but did not form high molecular
heterooligomeric complexes with Cav-1 [18].
5.TheNegativeRoleof (LipidRaft/Caveolar)
Cav-2inRegulatingLungEndothelial
Cell Proliferation
The possibilityfortheinvolvementofCav-2inregulating en-
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by the observation that Cav-2 KO mice develop a hyperpro-
liferative phenotype in the lungs involving vascular endothe-
lial growth factor receptor 2 (VEGFR-2 = Flk-1 in mouse)
positive cells [12]. Because Flk-1 is widely believed to be pre-
dominantly expressed in endothelial cells, this observation
suggests that Cav-2 may negatively regulate microvascular
endothelial cell proliferation in the lung. However, due to
the overall complexity of the in vivo system, it is impossible
to unequivocally conclude if Cav-2 directly regulates lung
microvascular endothelial cell proliferation. Therefore, we
immunoisolated and characterized pure populations of lung
endothelial cells from Cav-2 KO and wild-type (WT) mice
and directly compared their proliferation potential and the
expression or phosphorylation levels of cell cycle-associated
signaling proteins. These studies determined that Cav-
2 directly suppresses lung microvascular endothelial cell
proliferation, possibly via inhibition of extracellular signal
regulated kinase 1/2 (ERK1/2) phosphorylation, increased
expression of cyclin-dependent kinase (cdk) inhibitors
p16INK4 and p27Kip1, and activation (hypophosphory-
lation) of the retinoblastoma (Rb) protein, resulting in
a decreased cell-cycle progression [19]. Recently, another
group using a combination of miRNA, siRNA, and plasmid
overexpression approaches has conﬁrmed antiproliferative
function of Cav-2 in rat prostate endothelial cells (YPEN-1)
[20].
We are now investigating the mechanistic nature of this
negative regulation by Cav-2. Since Cav-2 almost entirely
targets to lipid rafts/caveolar microdomains in mouse lung
endothelial cells used in our experiments [21], our data
suggest that the inhibitory eﬀect of Cav-2 on endothelial cell
proliferation is most likely initiated in plasma membrane
lipid rafts and caveolae. However, additional mechanistic
studieswillberequiredtounequivocallyconcludeifthelatter
is always true.
How could the inhibitory signal be transduced from
caveolar Cav-2 to downstream target proteins regulating
endothelial cell proliferation? It may be either through the
negative eﬀect on some of many growth factor receptors that
are present in caveolae or even via a direct eﬀect on intra-
cellular proteins involved in cell proliferation. For example,
the N and to a lesser degree C-terminal ends of caveolae-
localized Cav-2 face the cytosol and could potentially
interactwithsignalingproteinslocatedincytosol,membrane
vesicles, and other compartments which can come in a close
proximity with caveolae.
6.(LipidRaft/Caveolar)Cav-2Suppresses
theTransformingGrowthFactor
Beta-InducedSignaling andInhibition of
Mouse LungEndothelialCell Proliferation
Our most recent ﬁndings suggest that the role of Cav-2 in
regulating lung microvascular EC proliferation is more com-
plex and appears to be context speciﬁc [21]. Speciﬁcally,
using a combination of WT and Cav-2 KO, along with retro-
viral re-expression approaches, we have determined that
Cav-2 may be a physiological inhibitor of antiproliferative
function and signaling of transforming growth factor beta
(TGF-β)inmouselungendothelialcells.Althoughtreatment
with TGF-β resulted only in a modest inhibitory eﬀect on
WT lung endothelial cells, it profoundly inhibited prolifer-
ation of Cav-2 KO lung endothelial cells. To conﬁrm the
speciﬁcity of the observed diﬀerence between WT and Cav-2
KO endothelial cells in response to TGF-β,w eh a v es t a b l yr e -
expressed human Cav-2 in Cav-2 KO endothelial cells using
a retroviral approach. Similar to WT endothelial cells, the
antiproliferative eﬀect of TGF-β was dramatically reduced
in the Cav-2 re-expressing endothelial cells. This reduced
antiproliferative eﬀect of TGF-β in Cav-2 positive cells was
demonstrated by three independent proliferation assays and
correlated with a loss of TGF-β-mediated upregulation
of p27 and subsequent reduction of the levels of hyper-
phosphorylated (inactive) form of the Rb protein in Cav-
2 re-expressing endothelial cells. Mechanistically, Cav-2
inhibits antiproliferative action of TGF-β by suppressing
Alk5/Smad2/3 pathway manifested by reduced magnitude
and length of TGF-β-induced Smad2/3 phosphorylation as
well asactivationofAlk5/Smad2/3targetgenes,plasminogen
activator inhibitor-1 and collagen type I in Cav-2-positive
endothelial cells. To examine possible changes in targeting
of TGF-β receptors (TβRs) or other components of TGF-
β signaling pathway to lipid raft and caveolar domains,
we performed detergent-free sucrose fractionation gradient.
Our preliminary data suggest that expression of Cav-2 does
not signiﬁcantly change targeting of TGF-β receptors type I,
Alk5 and Alk1 as well as Smad2/3 to caveolar and lipid raft
microdomains. However,additionalstudieswithcontrolver-
sus TGF-β-treated endothelial cells using various subcellular
fractionation and immunoﬂuorescence microscopy localiza-
tion techniques will be needed for a more comprehensive
analysis. One could possibly argue that perhaps the fact that
Cav-1 expression levels are reduced at least by c.a. 50% in
Cav-2 KO, relative to WT endothelial cells, could contribute
totheenhancedantiproliferativeeﬀectofTGF-βinCav-2KO
endothelial cells. This is, however, not the case, because the
levels of re-expressed Cav-2 in Cav-2 KO endothelial cells
were insuﬃcient to signiﬁcantly upregulate the expression
levels of Cav-1 or change its targeting to lipid raft/caveolar
microdomains. In addition, just as endogenousCav-2 in WT
endothelial cells, the re-expressed Cav-2 displayed normal
targeting to plasma membrane and lipid raft/caveolae and
did not aﬀect subcellular targeting of endogenous Cav-
1. Moreover, these low levels of re-expressed Cav-2 were
adequate to reduce TGF-β-mediated responses in Cav-2 re-
expressing cells to the levels that were comparable with
WT endothelial cells [21]. Thus, the negative regulation of
TGF-β signaling and function by Cav-2 is independent of
both the expression levels and targeting of Cav-1 to lipid
raft/caveolar microdomains. Further studies examining the
detailed mechanisms responsible for inhibitory regulation of
TGF-β-induced signaling and function inendothelialcellsby
Cav-2 will be necessary. For example, it will be important to
examine for possible interactions of Cav-2 and Cav-1 with
Alk5 or other components of TGF-β pathway in the absence
and presence of TGF-β.I na d d i t i o n ,i tw i l lb ei n t e r e s t i n g
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Alk5, TβRII, or accessory receptors such as endoglin and
β-glycan by Cav-2. Also, it will be important to examine
the speciﬁc role of previously identiﬁed serine and tyrosine
phosphorylation of Cav-2 [3, 16–18]. Finally, determining in
vivosigniﬁcanceofourresults,forexample,howourﬁndings
may translate into a possible role of Cav-2 in regulating
angiogenesis using various models of angiogenesis in which
TGF-β pathway plays an important role, is clearly warranted.
7.Can(LipidRaft/Caveolae-Localized)
Cav-2Be ConsideredasMolecularSwitchin
ControllingMouse LungEndothelial
CellProliferation?
It is important to reconcile the role for Cav-2 in inhibiting
TGF-β-mediated antiproliferative eﬀect in endothelial cells
[21] with previously described antiproliferative role of Cav-
2[ 19]. Although, in both cases, Cav-2 acts as an inhibitor,
the ﬁnal outcome depends on the speciﬁc context. Namely,
in our previous studies, cell proliferation was evaluated
only under optimal conditions, that is, in the absence of
known growth inhibitors [19]. Under these conditions, Cav-
2 dampens proproliferative eﬀect of serum and growth fac-
tors, resulting in inhibition of endothelial cell proliferation.
Conversely, in the presence of TGF-β, the role of Cav-2
couldswitch from anti- to proproliferative eﬀectthrough the
negative regulation of the growth inhibitory action of TGF-
β/Alk5/Smad2/3pathway[21].Thus, itisplausibletosuggest
that Cav-2 protein present in caveolae could act as molecular
switch counteracting excessive cell responses to both pro-
andantiproliferativesignals.Furtherstudieswillbenecessary
to solidify this newly proposed role for Cav-2 in endothelial
and possibly other cell types.
8.PositiveRoleof(Noncaveolar)Cav-2in
Insulin-StimulatedFibroblast Proliferation
Although in Cav-2 KO mice, adipose tissue remains normal
and the protein levels of insulin receptor-β are not altered
[22], the function of Cav-2 in cell-cycle regulation by insulin
was examined in human insulin receptor-overexpressing rat
1 ﬁbroblast (Hirc-B) cells, in which treatment with insulin
induced Cav-2 gene expression in a time-dependent man-
ner. Overexpression of Cav-1 in these cells resulted in
inhibition of cell proliferation [23]. Furthermore, insulin-
induced phosphorylation of Cav-2 on tyrosine 19, leading
to increased interaction between Cav-2 and phospho-ERK.
Interestingly,treatment withinsulin resultedintranslocation
of phospho-ERK and pY19-Cav-2 to the nucleus. Down-
regulation of Cav-2 with siRNA suppressed the insulin-
induced nuclear localization of ERK and attenuated the
ERK-mediated c-Jun and cyclinD1expression and DNAsyn-
thesis by insulin. Furthermore, insulin-induced interaction
of Cav-2 with phospho-ERK was prevented when tyrosine
19 was mutated to alanine. In addition, actin cytoskeleton
was shown to be involved in the nuclear translocation of
Cav-2-ERK complex. Thus, the authors concluded that the
tyrosine 19 phosphorylation of Cav-2 is required for actin
cytoskeleton-dependent ERK nuclear import [24]. In sub-
sequent study, the same group also reported that insulin-
activated ERKistranslocated tothenuclearenvelopeby Cav-
2 and associates with lamin A/C in the inner nuclear mem-
brane. Using site directed mutagenesis, they also determined
that the Ser154-Val 155-Ser156 domain on the C-terminal
of Cav-2 was essential for insulin—but not insulin growth
factor-induced tyrosine 19 phosphorylation of Cav-2 and
nuclear targeting of ERK and Cav-2 [25].
How could Cav-2 play an opposite role in regulating
endothelial and ﬁbroblast cell proliferation? The most likely
reason is subcellular targeting. Although lipid raft/caveolar
localization was not examined in HircB ﬁbroblasts, unlike
endothelial cells, HircB cells do not seem to express Cav-1
[23].Thus, it is reasonable to suggest that caveolaeare absent
in these cells and due to lack of Cav-1, Cav-2 localization is
limited to nonlipid raft intracellular compartments in the
absence or even nucleus upon stimulation with insulin. It
would be interesting to further elucidate these processes by
comparing the eﬀect of overexpressed Cav-2 in the absence
versus the presence of Cav-1 and to examine if Cav-2 inter-
acting with Cav-1 and thus localized to lipid raft/caveolar
microdomains is able to possibly dissociate from Cav-1
and translocate to intracellular compartments, in particular
nucleus in response to insulin.
9.Cav-2and HumanCancer
The Cav-2 gene was colocalized with the Cav-1 gene to the
locus D7S522 of human chromosome 7q31.1, a known frag-
ile site (FRA7G) that is frequently deleted in human cancers,
including squamous cell carcinomas of the head and neck,
prostate cancers, renal cell carcinomas, ovarian adenocarci-
nomas, colon carcinomas, and breast cancers [26]. Although
Cav-2 expression levels were unaltered by oncogenic trans-
formation [27, 28], Cav-2 expression was upregulated in
esophageal[29]andurothelialcarcinoma[30].Furthermore,
the expression of Cav-2 was associated with shorter survival
in stage I lung adenocarcinomas [31]. Cav-2 expression was
also closely associated with basal-like immunophenotype
and proved by univariate analysis to be a prognostic factor
of breast cancer [32, 33]. Recently, the number of caveolae
and the expression levels of Cav-2, Cav-1, and PTRF/cavin-1
were investigated in normal human prostate stromal, epithe-
lial cells, androgen-dependent (LNCaP), and androgen-
independent (PC3) cancer cell lines as well as in tissue
obtained from patients with benign prostatic hyperplasia
(BPH) and well-diﬀerentiated and poorly diﬀerentiated
prostate cancer. These studies revealed that the number of
caveolae was signiﬁcantly reduced in LNCaP and PC3 cells.
PTRF/cavin-1 expression levels were signiﬁcantly reduced in
both LNCaP and PC3 cells and in prostate cancer tissue.
In contrast to PTRF/cavin-1 of which expression levels
decreased, the expression levels of Cav-1 and -2 increased in
prostate cancertissue. Importantly, althoughbothCav-1and
-2 were nearly absent in androgen-dependent LNCaP cells,
the expression levels of Cav-2 but not Cav-1 were markedly
elevated in androgen-independent PC3 cells as compared to
normal prostate epithelial cells. Overall, this data suggestBiochemistry Research International 5
that changes in the plasma membrane involving loss of
caveolae and PTRF/cavin-1 expression occur during prostate
cancerprogression.Importantly,Cav-2isupregulatedduring
prostate cancer progression [34]. Since upregulation of Cav-
2 in PC3 cells coincides with the absence of caveolae, this
data suggests that noncaveolar Cav-2 could possibly play a
positive role in prostate cancer progression. Since PC3 still
express Cav-1, it is likely that Cav-2 still interacts with Cav-
1 and targets to lipid rafts microdomains although direct
studies examining the latter possibility will be required.
Interestingly, a most recent study using siRNA and overex-
pression approaches demonstrated that Cav-2could possibly
diﬀerentially aﬀect proliferation of various cell lines. For
example, overexpression of Cav-2 in HepG2 hepatocellular
carcinoma and siRNA knockdown in C6 glioma cell lines
reduced cell proliferation. Furthermore, overexpression of
Cav-2 in SH-SY5Y neuroblastoma and siRNA knockdown
in HeLa epithelial cervical cancer and A549 lung adeno-
carcinoma cell lines promoted cell proliferation [35]. Little
mechanistic insight is provided as to how Cav-2 could
diﬀerentially regulate proliferation in the above mentioned
cancer cell lines. However, studies focused on if and how
the above reported diﬀerences depend on lipid raft/caveolar
versus nonlipid raft/caveolar targeting of Cav-2 could shed
more light.
10.LipidRaft-versusNonlipid Raft-Localized
Cav-2andBacterialInvasion
Cav-2 has been shown to facilitate infection of murine lung
epithelial cell line MLE-12 with Pseudomonas aeruginosa and
thatlipidraft targetingand tyrosine phosphorylation ofCav-
2 as well as interaction with Csk and c-Src was important
[36, 37]. Speciﬁcally, siRNA-mediated knockdown of Cav-2
decreased[36],whileoverexpressionofWTbutnotY19/27F-
Cav-2increased theabilityofP. aeruginosa to invade MLE-12
cells. In addition, the siRNA knockdown of Cav-1 also
resulted in reduction of P. aeruginosa invasion. However,
unlike Cav-2 siRNA which did not change Cav-1 expression
level, Cav-1 siRNA reduced Cav-2 expression levels,
suggesting that Cav-2 rather than Cav-1 could be directly
responsible [36]. Lipid raft dependence of P. aeruginosa
invasion and Cav-2 phosphorylation was determined on
the basis of various pharmacological inhibitors, including
cholesterol aﬀecting agents such as methyl-β-cyclodextrin
or ﬁlipin [36, 37]. However, due to nonspeciﬁc nature of
pharmacological inhibitors used in this study, it would be
important to provide additional evidence for the speciﬁc
involvement of lipid raft-localized Cav-2 in the process.
For example, it would be vital to examine targeting of
endogenous and overexpressed WT- and Y19/27F-Cav-2
to plasma membrane lipid rafts/caveolae before and at
diﬀerent stages of MLE-12 cell invasion with P. aeruginosa
using sucrose ﬂoatation gradients and immunoﬂuorescence
microscopy.
In another study, using siRNA approach, it was demon-
strated that Cav-2, actin, E3 ubiquitin ligase, c-Cbl, and
clathrin but not Cav-1 is involved in invasion of Rickettsia
conorii in HeLa cells [38]. Considering that Cav-1 is required
for lipid raft/caveolar targeting of Cav-2, the negative eﬀect
of Cav-1 siRNA could suggest that nonlipid raft/caveo-
lar Cav-2 is responsible for facilitating invasion with this
pathogen.
The role of noncaveolar Cav-2 was also suggested in
chlamydial infection of various epithelial cell lines including
HeLaandFRTcells,where Cav-2associatedwith thechlamy-
dial inclusion independently of Cav-1 [39]. However, the
functional signiﬁcance of Cav-2 either in the uninfected cell
or in the chlamydial developmental cycle were not addressed
in this study.
11.Cav-2,LipidDroplets,and Metabolism
Lipid droplets are organelles that play important role in
lipid metabolism and beyond [40]. It was shown that under
certain conditions, Cav-2 can also be found in lipid droplets
[41, 42]. Speciﬁcally, overexpressed Cav-2 accumulated not
only in the Golgi apparatus but also in lipid droplets of
the transiently transfected FRT cells [42]. In another study,
it was also shown that Cav-2, especially its beta isoform,
is targeted to the surface of lipid droplets by immunoﬂu-
orescence and immunoelectron microscopy and by subcel-
lular fractionation. Brefeldin A treatment induced further
accumulation of Cav-2 along with Cav-1 in lipid droplets.
Analysis of mouse Cav-2 deletion mutants revealed that the
centralhydrophobicdomain(residues87–119)andtheNH2-
terminal (residues 70–86) and COOH-terminal (residues
120–150) hydrophilic domains are all necessary for the
targeting to lipid droplets. The NH2- and COOH-terminal
domains appeared to be important to membrane binding
andexitfromendoplasmicreticulum,respectively,indicating
that Cav-2 is synthesized and transported to lipid droplets as
a membrane protein. In conjunction with ﬁndings that lipid
droplets contain unesteriﬁed cholesterol and raft proteins,
the result suggeststhatthe lipid dropletsurface may function
as a membrane domain. It also suggests that lipid droplets
could be related to traﬃcking of lipid molecules mediated
by caveolins [41]. Although lipid metabolism is not the only
function assigned to lipid droplets [Fujimoto and Parton],
it is plausible to hypothesize that Cav2 present in lipid
droplets could play some role in lipid storage or even lipoid
metabolism. The question still remains as to what functional
role could be associated with targeting of Cav-2 to lipid
droplets besides potential involvement in lipid transport
or metabolism? Which factor(s) is/are responsible for this
preferred beta over alpha isoform of Cav-2 targeting to lipid
droplets? Another question is if targeting of beta isoform of
Cav-2 to lipid droplets plays a unique, possibly diﬀerent role
from that of alpha isoform.
As expected on the basis of lipid droplet targeting of
Cav-2, later studies also implicated Cav-2 in regulating lipid
metabolism due to changes in its expression levels associated
with obesity and type 2 diabetes mellitus or adenoviral
overexpression studies [43, 44]; however, the direct role of
Cav-2 and its alpha versus beta isoforms in these processes
remains still unclear.6 Biochemistry Research International
12.SelectedExamplesofOther Cell
Type-SpeciﬁcFunctionsofCav-2
Although originally only Cav-1 but not Cav-3 have been
shown to interact and form high molecular weight het-
erooligomeric complexes with Cav-2 [45], later studies have
shown that Cav-2 is coexpressed and may interact with Cav-
3 in neonatal cardiac myocytes [46]. Interestingly, other
ﬁndings show that although in ﬁbroblasts Cav-2 interacts
with Cav-1, but not -3, in myoblasts, all three caveolin
isoforms could be coimmunoprecipitated [47]. This lack or
presence of interaction for Cav-2 with Cav-3 in the above-
mentionedcelltypesisinterestingandmaysuggestthataddi-
tional interacting partner(s) could be absent in ﬁbroblasts
but present in cardiac myocytes and myoblasts that could be
responsible for such cell-speciﬁc diﬀerences.
Cav-2 has also been shown to regulate endocytosis and
traﬃcking of the M1 muscarinic acetylcholine receptor
(mAChR) in MDCK cells [48]. The mechanism of this reg-
ulation appears somewhat complicated. Speciﬁcally, asso-
ciation of the plasma membrane M1 mAChR with Cav-2
inhibits receptor endocytosis through the clathrin-mediated
pathway or retains the receptor in an intracellular compart-
ment, resulting in attenuated receptor traﬃcking [48].
Cav-2 has also been shown to be required for apical lipid
traﬃcking in the intestine of Caenorhabditis elegans [49].
Coimmunoprecipitation and ﬂuorescence microscopic
colocalization studies have revealed that Cav-2 interacts and
colocalizes with Connexin 43 in rat epidermal keratinocytes,
suggesting that both caveolins could regulate gap junctional
intercellular communication [50].
13.What CanWeLearnaboutSpeciﬁc
ContributionofCav-2to Lipid
Raft/Caveolar-MediatedCell/Tissue-Speciﬁc
Signalingand Functionfrom
StudieswithCav-2KOMice?
Generation of and studies involving Cav-2 KO mice started
revealing more information as to the pathophysiological sig-
niﬁcanceofCav-2.Initially,itwasshown thatCav-2KOmice
develop hyperplasia in the lung associated with an increased
number of Flk-1-positive, most likely endothelial cells [12],
suggesting a role for Cav-2 in regulating lung endothelial
cell proliferation and/or diﬀerentiation. As a consequence,
Cav-2 KO mice are exercise intolerant, presumably due to
an impaired gas exchange through the thickened alveolar
septa.Interestingly,similarhyperproliferativephenotypewas
previously observed in Cav-1 KO mice [7]. However, the
expression levels of Cav-2 in the lung of Cav-1 KO mice
diminish to ca. 5% of the respective expression levels in
WT mice. In contrast, the expression level of Cav-1 in
the lung of Cav-2 KO mice is only reduced to 50%, and
Cav-1 heterozygotes expressing comparable level of Cav-
1t ot h a to b s e r v e di nC a v - 2K Om i c ed on o td e v e l o p
hyperproliferative phenotype [12]. In addition, studies by
Jasmin et al. 2004 have determined that similar to Cav-1 KO,
STAT3 is hyperphosphorylated, and cyclin D1 and D3 levels
were dramatically upregulated inthe lungsofCav-2KOmice
[51].Overall,theseﬁndingsimplicatethelackofCav-2asthe
direct cause of the hyperproliferative phenotype observed in
the lungs of both Cav-1 and Cav-2 KO mice. Moreover, since
Cav-2 targeting to plasma membrane caveolae and lipid rafts
depends on Cav-1, it is conceivable to suggest that proper
targeting of Cav-2 to lipid raft/caveolar microdomains is
necessary for Cav-2 to maintain physiological homeostasis
in the lung by preventing the hyperproliferative phenotype
and associated remodeling which can be found in the lungs
of Cav-2 KO mice.
Studies of Woodman et al. [52], revealed increased num-
ber of hematoxylin/eosin positive vessels in basic ﬁbroblast
growth factor-loaded matrigel plugs implanted to Cav-2
KO relative to WT mice. These data suggest that loss of
Cav-2 could enhance basic ﬁbroblast growth factor-induced
angiogenesis in vivo. Additional studies examining the role
of Cav-2 in postnatal angiogenesis will be required.
Skeletal muscle abnormalities including tubular aggre-
gate formation, mitochondrial aggregation, and increased
numbers of M-Cadherin positive satellite cells that are skele-
tal muscle-speciﬁc stem/precursor cells were also reported
i nC a v - 2K Om i c e[ 53]. Because a similar phenotype was
observed in Cav-1 KO mice and due to previously discussed
dependence of Cav-2 on Cav-1, one could suggest that like
in the lung, Cav-2, not Cav-1, is also directly responsible
for maintaining normal phenotype in skeletal muscle. Again,
targeting to lipid raft/caveolar microdomains should be
essential for Cav-2 to perform this important physiological
function.
In another study, an increased number of Ki67-positive
nuclei in the subventricular zone (SVZ) of Cav-2 KO brains
could be observed, suggesting that Cav-2 may play a negative
roleinregulatingproliferationofadultneuralstemcells[54].
Similar data were obtained with Cav-1 KO mice, and since
Cav-2 traﬃcking and localization to lipid rafts and caveolae
depends on Cav-1 but not vice versa, as it is the case with
pulmonary and muscle phenotypes, Cav-2 localizing to lipid
raftsorcaveolaecouldbedirectlyinvolvedinregulatingadult
neural stem cell proliferation.
The most recent studies have reported increased sensitiv-
ityofCav-2KObutnotCav-1KOmicetoendotoxemiaupon
intraperitoneal injection with lipopolysaccharide (LPS) [55].
This augmented sensitivity of Cav-2 KO mice to LPS was
associated with increased intestinal injury and intestinal
permeability and correlated with enhanced expression of
iNOS, production of nitric oxide (NO), and tyrosine 701
phosphorylation of STAT-1. In contrast to Cav-2, Cav-1 KO
mice did not display an altered intestinal permeability and
had decreased iNOS expression, NO production, and STAT-
1 phosphorylation at tyrosine 701 compared to WT mice.
Since Cav-2 is almost completely absent in Cav-1 KO mice,
the authors concluded that not just the absence of Cav-2,
but also the balance between Cav-1 and -2 is important for
iNOS expression and ultimately for sepsis outcome [55].
Thus, unlike in previously reported role for Cav-2 in the
lung,skeletalmuscle,andadultneuralstemcellproliferation,
whereCav-2playeddirectrole,thisnewdataalsosuggestthat
the ratio between the expression levels of Cav-1 and -2 couldBiochemistry Research International 7
be the predominant factor responsible for the ﬁnal outcome
of the LPS challenge.
Further studies will be required to precisely determine
pathophysiological and mechanistic aspects of the reported
phenotypes involving Cav-2 KO mice.
14.Conclusionand FutureDirections
Multiple new ﬁndings from functional and mechanistic
studies involving both in vivo and cell-based models have
been recently reported, suggesting that one of the major
protein components of plasma membrane caveolae, Cav-2,
is not just an accessory protein, but it is also an important
contributor to lipid raft- and caveolae-mediated signaling
and function. The evidence continues to accumulate sug-
gesting that in most cases in which loss or reduction of
Cav-2 or Cav-1 results in a similar phenotype, Cav-2 plays
am o r ed i r e c tr o l e .T h es i m p l er e a s o ni st h a tu n l i k eC a v - 1
which targets lipid rafts and caveolae on its own, interaction
with Cav-1 is required for Cav-2 targeting to caveolae.
Thus, whenever Cav-1 is lost or signiﬁcantly reduced, Cav-
2 loses its lipid raft/caveolar location and function, for which
propertargeting ofCav-2to lipid raft/caveolaeisessential. In
contrast, when Cav-2 is lost or reduced, Cav-1 still targets
to lipid rafts/caveolae and retains all functions which do
not depend on Cav-2. Despite considerable progress in the
ﬁeld, there are many questions to be answered. For example,
what is the speciﬁc contribution of Cav-2 to lipid raft- and
caveolae-mediated regulation of cell signaling and function?
Exactly,howCav-2performs itsfunctionsincaveolae?Which
speciﬁc domains of Cav-2 are mostly involved and what is
the contribution of each phosphorylation site identiﬁed on
Cav-2? Are there any signaling proteins of which targeting
to caveolae depends more directly on Cav-2 than Cav-1 that
could explain previously reported functions of Cav-2? What
is the functional signiﬁcance of serine 23 phosphorylation,
which strictly depends on targeting of Cav-2 to caveolae
in epithelial and endothelial cells? Are there additional
posttranslationalmodiﬁcationsofCav-2inadditiontoserine
23 which occur when Cav-2 reaches plasma membrane
lipid rafts and caveolae? How important is tyrosine 19 and
27 phosphorylation or perhaps dephosphorylation of Cav-
2 for the cell-speciﬁc role of lipid rafts/caveolae? How is
it possible for tyrosine phosphorylated-Cav-2 to associate
with caveolae/lipid rafts without being able to form high
molecularheterooligomericcomplexeswith Cav-1?Whatare
the interacting partners for Cav-2 necessary for inhibition
of lung endothelial cell proliferation and TGF-β-induced
signaling and function? What new phenotypes are waiting to
bediscoveredinproperlychallengedCav-2KOmiceandhow
theymayhelptobetterunderstandthecontributionofCav-2
to cell- and tissue-speciﬁc role of caveolae and lipid rafts?
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